Sensus Healthcare Reports Q3 2025 Financial Results

Sensus Healthcare, Inc. ( (SRTS) ) has released its Q3 earnings. Here is a breakdown of the information Sensus Healthcare, Inc. presented to its investors.

Sensus Healthcare, Inc. is a medical device company that specializes in non-invasive treatments for skin conditions, particularly using superficial radiotherapy (SRT) technology. The company operates within the healthcare sector, focusing on innovative solutions for oncological and non-oncological skin conditions.

In its third-quarter 2025 financial results, Sensus Healthcare reported revenues of $6.9 million, a decrease from the previous year. The company highlighted the establishment of new coding by the Centers for Medicare & Medicaid Services (CMS) for SRT, which is expected to enhance reimbursement certainty and support adoption of their technology.

Key financial metrics for the quarter included a net loss of $0.9 million, or $0.06 per share, compared to a net income in the same period last year. The company shipped 16 SRT systems, including international shipments to China, and recorded a significant increase in treatment volumes under its Fair Deal Agreement. Despite a decrease in revenue, Sensus Healthcare maintains a strong cash position with $24.5 million and no debt.

The company has been actively pursuing strategic priorities, including expanding internationally and increasing the utility of its SRT technology. A recent study published in Dermatologic Therapy demonstrated the efficacy of combining SRT with punch excision for treating keloids, further validating the versatility of their technology.

Looking forward, Sensus Healthcare is optimistic about the future, with nearly 100 systems in inventory ready to meet market demand. The company is poised for growth, supported by recent CMS coding changes and ongoing international expansion efforts.